Circular RNAs (circRNAs) are covalently linked single-stranded RNAs, compared to linear counterparts that are relatively abundant, conserved, stable, and specific. Previously, most studies have revealed that circRNAs function in gene expression processes and participate in the pathogenesis of cancers, cardiovascular diseases, and neurological diseases. With advances in biotechnology, more biological functions of circRNAs have been found in several signaling pathways that are related to tumorigenesis, immunity, and metabolism. Recently, many circRNAs have been reported to be expressed abnormally and play important roles in the progression of autoimmune diseases. Thus, circRNAs may not only serve as potential biomarkers but also act as immune regulators and offer potential opportunities for therapy. This review briefly introduces the properties as well as the functions of circRNAs in different stages of gene expression. In addition, this article summarizes the available knowledge about abnormally expressed circRNAs in different autoimmune diseases and discusses their potential roles in these diseases, which helps us understand their regulatory mechanisms and provides future research perspectives.
Follicular regulatory T (Tfr) cells are the regulatory T cell subset mainly localized in the germinal center (GC), acting as modulators of GC responses. They can disrupt Tfh cell- and B cell-linked recognition, induce Tfh apoptosis, and suppress B cell function. Evidences show that dysregulated Tfr cells are associated with the disease activity index and serum autoantibody levels, influencing the development of systemic lupus erythematosus (SLE). This review focuses on the interaction among Tfr, Tfh, and B cells, summarizes the characterization and function of Tfr cells, concludes the imbalance of CD4+T subsets in SLE, and presents potential therapies for SLE. In general, we discuss the roles of Tfr cells in the progress of SLE and provide potential treatments.
16 November 2007 in Journal of Physics D: Applied Physics
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which is mainly caused by the imbalance of immune cells. Current treatment regimens predominately rely on corticosteroids and immunosuppressive agents, accompanied by various side effects. Interleukin-2 (IL-2) is deemed an important cytokine for innate immune cells and adaptive immune cells, especially for the promotion of Treg cells. By combining IL-2/IL-2R system with engineered T cell-based immunotherapies to enhance the therapeutic efficacy of engineered T cells shows its potential in autoimmune diseases. But the pleiotropy of IL-2 may cause simultaneous stimulation and systemic toxicity, limiting its therapeutic use. There is a growing focus on using IL-2 in combination strategies for synergistic immune enhancement. In this article, we review the IL-2/IL-2R signaling, including IL-2 dependent signaling and IL-2 independent signaling, and discuss its functions in regulation of different immune cells. In addition, we summarize major clinical application of low-dose IL-2 treatment in SLE with or without other agents, such as rapamycin, tocilizumab and rituximab, present the IL-2 variants and fusion proteins designed for SLE, and highlight the future trends for research on these cytokine-based immunotherapies. It will help to design further optimized IL-2-based therapy for SLE.
The main purpose of this article is to investigate the bursting oscillations of the medical shaking tables resulted from friction in practical application. Using the theoretical method of linear loading, the analytic expression of friction acting on an eccentric turntable is derived in detail. Besides, through numerical simulation, the decisive role of friction in bursting oscillations is verified. On this basis, several practical operation plans are proposed to eliminate harmful vibrations. Last but not least, the effectiveness of theoretical methods is validated through example calculations in cases with special parameters.
N6‐methyladenosine (m6A) modification is the most widespread RNA internal modification involved in RNA metabolism, participating in cell biology and immune responses. In the early stage of systemic lupus erythematosus (SLE), m6A modification can affect the production of autoantibodies by regulating the differentiation of T follicular helper (Tfh) cells and the generation of autoreactive B cells. With the development of SLE, its subsequent action in immune complexes (ICs)‐deposited tissues is the promotion of excessive fibrosis, causing progressive organ damage. TGF‐β is the central driver activating fibroblasts, inducing epithelial‐to‐mesenchymal transition (EMT), and promoting extensive extracellular matrix (ECM) deposition via the SMAD pathway, ultimately leading to tissue fibrosis and organ damage. m6A regulators can act on both upstream and downstream components of the TGF‐β signaling pathway. They can synergize with TGF‐β transcription factors to control the amplification of TGF‐β signaling. Furthermore, they can work with target molecules downstream of the TGF‐β receptor (TGF‐βR) to tune TGF‐β/SMAD pathway activity, increasing the expression of profibrotic transcripts. It is suggested that inhibition of m6A modification targeting the TGF‐β signaling pathway can effectively reduce EMT and fibrosis in multiple organs, especially in the kidney, improving the long‐term prognosis of SLE patients. In this review, we focus on the role of TGF‐β in the pathogenesis of SLE, the mechanism by which m6A modifications affect the TGF‐β signaling pathway, and its impact on EMT and fibrosis in different organs, trying to provide a new treatment strategy for the control of SLE symptoms.